Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACST NASDAQ:ANIX NASDAQ:ATYR NASDAQ:FATE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$3.11$3.22$1.98▼$3.60$29.23M1.5222,722 shs12,261 shsANIXANIXA BIOSCIENCES$3.60+2.3%$3.10$2.07▼$4.20$115.87M0.5886,943 shs294,311 shsATYRaTyr Pharma$1.08+6.4%$5.20$1.00▼$7.29$99.46M1.0112.25 million shs45.98 million shsFATEFate Therapeutics$0.95-0.5%$1.09$0.66▼$4.20$110.23M2.211.32 million shs841,705 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%0.00%+35.79%ANIXANIXA BIOSCIENCES+20.14%+18.12%+18.52%-4.35%+5.07%ATYRaTyr Pharma-83.25%-81.50%-79.39%-80.35%-46.84%FATEFate Therapeutics-0.76%-1.06%-12.31%-20.35%-76.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$3.11$3.22$1.98▼$3.60$29.23M1.5222,722 shs12,261 shsANIXANIXA BIOSCIENCES$3.60+2.3%$3.10$2.07▼$4.20$115.87M0.5886,943 shs294,311 shsATYRaTyr Pharma$1.08+6.4%$5.20$1.00▼$7.29$99.46M1.0112.25 million shs45.98 million shsFATEFate Therapeutics$0.95-0.5%$1.09$0.66▼$4.20$110.23M2.211.32 million shs841,705 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%0.00%0.00%+35.79%ANIXANIXA BIOSCIENCES+20.14%+18.12%+18.52%-4.35%+5.07%ATYRaTyr Pharma-83.25%-81.50%-79.39%-80.35%-46.84%FATEFate Therapeutics-0.76%-1.06%-12.31%-20.35%-76.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma 3.00Buy$10.00221.54% UpsideANIXANIXA BIOSCIENCES 3.00Buy$9.00150.00% UpsideATYRaTyr Pharma 2.17Hold$23.252,052.78% UpsideFATEFate Therapeutics 2.14Hold$3.30247.11% UpsideCurrent Analyst Ratings BreakdownLatest ACST, ATYR, ANIX, and FATE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025ATYRaTyr PharmaLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/15/2025ATYRaTyr PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight9/15/2025ATYRaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral9/15/2025ATYRaTyr PharmaLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform9/15/2025ATYRaTyr PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral9/11/2025ANIXANIXA BIOSCIENCESHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.009/9/2025ANIXANIXA BIOSCIENCESD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/22/2025ATYRaTyr PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $17.008/19/2025ANIXANIXA BIOSCIENCESD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/13/2025FATEFate TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$4.00 ➝ $2.508/5/2025ANIXANIXA BIOSCIENCESD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti PharmaN/AN/AN/AN/A$6.57 per shareN/AANIXANIXA BIOSCIENCES$210K564.34N/AN/A$0.47 per share7.66ATYRaTyr Pharma$230K460.13N/AN/A$0.83 per share1.30FATEFate Therapeutics$13.63M8.04N/AN/A$2.80 per share0.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-$12.85M-$1.44N/AN/AN/AN/A-13.61%-11.56%N/AANIXANIXA BIOSCIENCES-$12.55M-$0.350.00∞N/AN/A-67.45%-59.18%N/AATYRaTyr Pharma-$64.02M-$0.800.00N/AN/AN/A-93.69%-68.83%11/6/2025 (Estimated)FATEFate Therapeutics-$186.26M-$1.450.00N/AN/A-2,025.05%-50.95%-36.76%11/11/2025 (Estimated)Latest ACST, ATYR, ANIX, and FATE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/10/2025Q3 2025ANIXANIXA BIOSCIENCES-$0.10-$0.07+$0.03-$0.07N/AN/A8/12/2025Q2 2025FATEFate Therapeutics-$0.35-$0.29+$0.06-$0.29$1.16 million$1.91 million8/7/2025Q2 2025ATYRaTyr Pharma-$0.18-$0.22-$0.04-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/AANIXANIXA BIOSCIENCESN/AN/AN/AN/AN/AATYRaTyr PharmaN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A7.867.86ANIXANIXA BIOSCIENCESN/A8.458.45ATYRaTyr Pharma0.015.635.63FATEFate TherapeuticsN/A8.048.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma6.08%ANIXANIXA BIOSCIENCES29.13%ATYRaTyr Pharma61.72%FATEFate Therapeutics97.54%Insider OwnershipCompanyInsider OwnershipACSTAcasti Pharma13.51%ANIXANIXA BIOSCIENCES25.30%ATYRaTyr Pharma3.70%FATEFate Therapeutics5.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma329.40 million8.77 millionNot OptionableANIXANIXA BIOSCIENCES532.92 million24.59 millionOptionableATYRaTyr Pharma5397.99 million94.36 millionOptionableFATEFate Therapeutics550115.33 million108.98 millionOptionableACST, ATYR, ANIX, and FATE HeadlinesRecent News About These CompaniesJacobs Levy Equity Management Inc. Acquires 616,336 Shares of Fate Therapeutics, Inc. $FATESeptember 13 at 3:41 AM | marketbeat.comLeerink Partners Sticks to Its Buy Rating for Fate Therapeutics (FATE)September 11, 2025 | theglobeandmail.comWalleye Capital LLC Decreases Stock Position in Fate Therapeutics, Inc. $FATESeptember 9, 2025 | marketbeat.comNuveen LLC Invests $300,000 in Fate Therapeutics, Inc. $FATESeptember 8, 2025 | marketbeat.comResearch Analysts Offer Predictions for FATE Q3 EarningsSeptember 7, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives $3.30 Consensus Price Target from BrokeragesSeptember 7, 2025 | americanbankingnews.comLeerink Partnrs Brokers Increase Earnings Estimates for FATESeptember 7, 2025 | americanbankingnews.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of "Hold" by BrokeragesSeptember 5, 2025 | marketbeat.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)September 3, 2025 | globenewswire.comFate Therapeutics: Recent Update Met With Selling, But Positives ExistAugust 29, 2025 | seekingalpha.comFY2026 EPS Estimates for FATE Decreased by Cantor FitzgeraldAugust 24, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Stock Rating Upgraded by Wall Street ZenAugust 19, 2025 | marketbeat.comQ3 EPS Forecast for Fate Therapeutics Raised by AnalystAugust 17, 2025 | marketbeat.comFate Therapeutics Second Quarter 2025 Earnings: Beats ExpectationsAugust 14, 2025 | finance.yahoo.comFate Therapeutics price target lowered to $2.50 from $4 at Wells FargoAugust 13, 2025 | msn.comFate Therapeutics reports Q2 EPS (29c), consensus (34c)August 12, 2025 | msn.comFate Therapeutics Announces Corporate Restructuring PlanAugust 12, 2025 | msn.comFate Therapeutics: Q2 Earnings SnapshotAugust 12, 2025 | sfgate.comFate Therapeutics to Cut 12% of Workforce, 2Q Loss NarrowsAugust 12, 2025 | marketwatch.comFate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue EstimatesAugust 12, 2025 | zacks.comFate Therapeutics Reports Second Quarter 2025 Financial Results and Business UpdatesAugust 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20253 Under-the-Radar Biotechs Under $5 That Could Soar 200%By Chris Markoch | September 9, 2025These 3 Tech Stocks Just Supercharged Their BuybacksBy Leo Miller | September 16, 2025ACST, ATYR, ANIX, and FATE Company DescriptionsAcasti Pharma NASDAQ:ACSTAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.ANIXA BIOSCIENCES NASDAQ:ANIX$3.60 +0.08 (+2.27%) Closing price 04:00 PM EasternExtended Trading$3.52 -0.08 (-2.08%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.aTyr Pharma NASDAQ:ATYR$1.08 +0.07 (+6.40%) Closing price 04:00 PM EasternExtended Trading$1.08 -0.01 (-0.46%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Fate Therapeutics NASDAQ:FATE$0.95 -0.01 (-0.53%) Closing price 04:00 PM EasternExtended Trading$0.97 +0.02 (+1.61%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
